PF-06873600 manufacturers
- PF-06873600
-
- $52.00
-
2026-07-27
- CAS:2185857-97-8
- Purity: 99.55%
- Supply Ability: 10g
- PF-06873600
-
-
2026-06-30
- CAS:2185857-97-8
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
- PF-06873600
-
-
2023-05-26
- CAS:2185857-97-8
- Min. Order: 100mg
- Purity: 95%
- Supply Ability: 1kg
|
| | PF-06873600 Basic information |
| Product Name: | PF-06873600 | | Synonyms: | PF-06873600;Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)-4-piperidinyl]amino]-;Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[[1-(methylsulfonyl)-4-piperidinyl]amino]（PF-06873600）;6-(Difluoromethyl)-8-((1R,2R)-2-hydroxy-2-methylcyclopentyl)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one;Ebvaciclib (PF-06873600);PF06873600,PF 06873600;PF-06873600, 10 mM in DMSO;Ebvaciclib | | CAS: | 2185857-97-8 | | MF: | C20H27F2N5O4S | | MW: | 471.52 | | EINECS: | | | Product Categories: | | | Mol File: | 2185857-97-8.mol |  |
| | PF-06873600 Chemical Properties |
| Boiling point | 634.0±65.0 °C(Predicted) | | density | 1.47±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:15.0(Max Conc. mg/mL);31.81(Max Conc. mM) | | form | A solid | | pka | 14.69±0.40(Predicted) | | color | White to light yellow | | InChIKey | QIEKHLDZKRQLLN-FOIQADDNSA-N | | SMILES | C1(NC2CCN(S(C)(=O)=O)CC2)=NC=C2C=C(C(F)F)C(=O)N([C@@H]3CCC[C@]3(O)C)C2=N1 |
| | PF-06873600 Usage And Synthesis |
| Description | PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.
PF-06873600 is an inhibitor of cyclin-dependent kinase 2 (CDK2), CDK4, and CDK6 with Ki values of 0.1, 1.2, and 0.1 nM, respectively. It also blocks the phosphorylation of retinoblastoma protein (RB1) and limits the proliferation of OVCAR-3 ovarian cancer cells with EC50s of 19 and 45 nM, respectively. | | Uses | PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity[1][2]. | | Mechanism of action | PF-06873600 is taken as a tablet by mouth. PF-06873600 is a cancer growth blocker targeting specific proteins called Cyclin-Dependent Kinase 2, 4, and 6 (CDK2/4/6). It works by stopping or preventing the action of these proteins, which stimulate cancer cells to grow and divide. PF-06873600 selectively targets, binds to, and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. CDKs, ATP-dependent serine/threonine kinases that are essential regulators of cell cycle progression and cellular proliferation are frequently overexpressed in tumour cells.
| | IC 50 | CDK2: 0.09 nM (Ki); CDK4: 0.13 nM (Ki); CDK6: 0.16 nM (Ki) | | References | [1] US 2018/0044344 A1.
[2] NCI Drug Dictionary |
| | PF-06873600 Preparation Products And Raw materials |
|